Publication Name	World Journal of Gastroenterology
Manuscript ID	11246
Country	Italy

Received	2014-05-11 11:47
Peer-Review Started	2014-05-11 21:26
To Make the First Decision	2014-06-18 17:21
Return for Revision	2014-06-23 08:26
Revised	2014-07-16 04:02
Second Decision	2014-09-05 16:40
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-09-05 17:09
Articles in Press	2014-09-05 17:25
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-11-20 17:29
Publish the Manuscript Online	2014-12-10 15:52

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease
Manuscript Source	Invited Manuscript
All Author List	Alessandro Federico, Claudio Zulli, Ilario de Sio, Anna Del Prete, Marcello Dallio, Mario Masarone and Carmela Loguercio
Funding Agency and Grant Number
Corresponding Author	Alessandro Federico, MD, PhD, Department of Clinical and Experimental Medicine F. Magrassi e A. Lanzara, Hepatogastroenterology Division, Interuniversity Research Centre on Food, Nutrition and the Gastrointestinal Tract (CIRANAD) - Second University of Naples, Via Pansini 5, 80131 Naples, Italy. alessandro.federico@unina2.it
Key Words	Non-alcoholic steatohepatitis; Non-alcoholic fatty liver disease; Fatty liver; Steatosis; Emerging drugs
Core Tip	At the moment, there is no standardized treatment for non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH); the first-line approach remains lifestyle changes (diet and physical exercise). The high risk of complications associated with NAFLD/NASH, such as cardiovascular diseases and the incidence of hepatocellular carcinoma, make it necessary to apply appropriate medications to stop the progression of the disease. Considering the pathogenetic pathways known today, several therapeutic targets have been proposed, including some that look very promising; still, innovative pharmacological strategies are absolutely needed. Below, we report the real efficacies of fatty liver therapies and the most recent studies investigating this field.
Publish Date	2014-12-10 15:52
Citation	Federico A, Zulli C, de Sio I, Del Prete A, Dallio M, Masarone M, Loguercio C. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(45): 16841-16857
URL	http://www.wjgnet.com/1007-9327/full/v20/i45/16841.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i45.16841

Full Article (PDF)	WJG-20-16841.pdf
Full Article (Word)	WJG-20-16841.doc
Manuscript File	11246-Review.doc
Answering Reviewers	11246-Answering reviewer.pdf
Copyright License Agreement	11246-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	11246-Language certificate.pdf
Peer-review Report	11246-Peer reviews.pdf
Scientific Misconduct Check	11246-CrossCheck.jpg
Scientific Editor Work List	11246-Scientific editor work list.pdf